Jason Luke
Section of Hematology / Oncology
Assistant Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Training

DegreeYearInstitutionArea
BS2002University of IowaMicrobiology
MD2006Rosalind Franklin University of Medicine and Science 
Internship2007Boston University Medical CenterInternal Medicine
Residency2009Boston University Medical CenterInternal Medicine
Fellowship2012Weill Cornell Medical CollegeMedicine
Fellowship2012Memorial Sloan-Kettering Cancer CenterMedical Oncology

Academic Interests

Dr. Luke's research focuses on translational therapeutic advances for melanoma and early phase drug development, particularly immunotherapy. He serves as the national Study Chair for the only on-going national clinical trial for patients with advanced uveal (ocular) melanoma and is the principal investigator of several clinical trials of immunotherapy and targeted molecular therapies for melanoma and advanced cancer.


Clinical Interests

Management of patients with melanoma and advanced solid tumor malignancies.


Representative Publications

  1. Antitumor Granuloma Formation by CD4+ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab.Luke JJ, Lezcano C, Hodi FS, Murphy GF.J Clin Oncol. 2014 Mar 10.
  2. Biology of advanced uveal melanoma and next steps for clinical therapeutics.Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD.Pigment Cell Melanoma Res. 2014 Aug 12.
  3. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, Johnson BE; Cell Free DNA Working Group.J Natl Cancer Inst. 2014 Aug 8;106(8).
  4. The Biology and Clinical Development of MEK Inhibitors for Cancer.Luke JJ, Ott PA, Shapiro GI. Drugs. 2014 Dec;74(18):2111-28.
  5. Drug-Associated Dermatomyositis Following Ipilimumab Therapy: A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade.Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, Vleugels RA.JAMA Dermatol. 2014 Oct 15



More Information

For more information about Dr. Jason Luke publications and research collaborations , please click here